Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Concord Biotech Limited
CONCORDBIOConcord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. Address: 16th Floor, B-Wing, Ahmedabad, India, 380015
Analytics
Precio Objetivo de WallStreet
162 710.20 INRRelación P/E
53.76Rentabilidad por dividendo
0.52 %Cifras clave CONCORDBIO
- Margen de Beneficio
- Ingresos Totales
- Beneficio Bruto
- Ingresos Netos
Análisis de dividendos CONCORDBIO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
29.00 %Tendencia del payout CONCORDBIO
- Relación de Pago
- Dividends
- Rentabilidad por dividendo
Valoración de la acción CONCORDBIO
- Relación Precio/Ventas
- Relación PE
- Relación Precio/Valor en Libros
- Relación Corriente
- Relación de Deuda
Finanzas CONCORDBIO
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dinámica | |
Ingresos Totales | 5 064 086 849 INR | 5 970 727 485 INR | 7 002 534 914 INR | 8 433 092 579 INR | 9 865 240 654 INR | ||
Ingresos Operativos | 1 917 552 245 INR | 3 033 387 272 INR | 2 411 379 066 INR | 3 227 504 943 INR | 6 189 491 980 INR | ||
Ingresos Netos - (CF) | 1 671 577 909 INR | 2 321 727 180 INR | 1 729 075 758 INR | 2 373 113 413 INR | 3 045 428 578 INR | ||
BPA Básico Normalizado | 0.19 INR | 0.26 INR | 0.19 INR | 0.27 INR | 0.34 INR | ||
Dividendo por Acción | 0.00 INR | 0.00 INR | 0.00 INR | 0.00 INR | 8.59 INR | ||
Relación de Pago | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 29.50 % | ||
Total de Activos | 9 296 467 048 INR | 11 688 808 730 INR | 12 976 247 552 INR | 14 964 888 829 INR | 16 810 556 497 INR | ||
Total de Pasivos | 1 683 132 824 INR | 1 810 563 036 INR | 2 071 502 479 INR | 2 213 947 203 INR | 1 720 515 808 INR | ||
Relación de Deuda | 0.18 | 0.16 | 0.16 | 0.15 | 0.10 | ||
Total de Activos Corrientes | 450 928 261 INR | 6 001 309 971 INR | 6 253 551 057 INR | 7 192 929 057 INR | 8 858 745 380 INR | ||
Total de Pasivos Corrientes | 1 137 649 952 INR | 1 045 171 117 INR | 1 533 749 280 INR | 1 896 290 866 INR | 1 405 126 901 INR | ||
Relación Corriente | 0.40 | 5.74 | 4.08 | 3.79 | 6.31 | ||
Relación Rápida | -0.57 | 4.29 | 2.82 | 2.69 | 4.84 | ||
Rentabilidad sobre Activos | 17.98 % | 19.86 % | 13.32 % | 15.86 % | 18.12 % | ||
Cobertura de Intereses FFO | 166.22 | 471.80 | 45.09 | 72.99 | 131.90 | ||
Relación P/E - P/E (LTM) | - | - | - | - | 53.48 | ||
Rentabilidad por dividendo (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.39 % | ||
Rendimiento de Recompra (LTM) | - | - | - | - | - |